Pfizer Inc. will acquire approximately 8.3 million shares in Icagen Inc. at a share price of $6 to become the majority shareholder in the company. Icagen is developing its pipeline of drugs targeted at ion channels for pain disorders, and three of its targets are covered by a 2007 collaboration agreement with Pfizer.